02 2014 – Coming soon

We would like to thank our readers, subscribers and collaboration partners for a fruitful and eventful Q1 + Q2 2026, and we wish you all a most wonderful summer!

The European Commission (EC) has granted marketing authorisation for Wegovy pill (once-daily oral semaglutide 25 mg) for the treatment of adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity.

Mendus has signed an agreement with the South Australian Health and Medical Research Institute (SAHMRI) to support preparations for the Phase 2 VITAL-TFR2 trial with the company’s lead product vididencel in chronic myeloid leukemia (CML).

Presentations at the Alzheimer's Association International Conference (AAIC) show a field moving rapidly forward both with regard to treatments and diagnostics. 

Maria Ekdahl brings more than 20 years of senior finance leadership experience, including her current role as CFO of Nasdaq Stockholm-listed pharmaceutical company, Infant Bacterial Therapeutics, and will join Biovica on October 14, 2026.

Navinci Diagnostics has initiated a pilot project together with Lumito to evaluate the possibilities of combining the companies’ respective technologies within advanced tissue analysis.

BioArctic’s partner Eisai has announced that the US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for a once weekly lecanemab irmb subcutaneous injection (US brand name: Leqembi Iqlik) as a starting dose for the treatment of early Alzheimer’s disease.